12 Best ADR Stocks To Invest In According to Analysts

Page 7 of 11

5. AstraZeneca PLC (NASDAQ:AZN)

Upside Potential: 33.26%

AstraZeneca PLC (NASDAQ:AZN) is a leading biopharmaceutical company that is dedicated to developing, manufacturing, and selling prescription medicines for a wide range of medical conditions. The company’s diverse portfolio of treatments is focused on three key therapeutic areas: oncology, cardiovascular, renal, and metabolism (CVRM), and respiratory and immunology.

AstraZeneca PLC’s (NASDAQ:AZN) growth is driven by its strong performance in oncology, where its therapies are experiencing strong demand and driving revenue growth. The company’s CVRM therapeutic division is also performing well. Additionally, the company’s rare disease therapeutic division is expanding, driven by increasing sales of Ultiris and Soliris. The company’s weight management pipeline, including AZD5004 and AZD6234, also shows significant growth potential, especially with strategic hires and advancements in clinical trials.

AstraZeneca PLC (NASDAQ:AZN) has an ambitious long-term goal, aiming to reach $80 billion in revenue by 2030, and plans to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues. The company is expanding in emerging markets and is confident in its ability to achieve this goal.

Page 7 of 11